Dr Reddy’s Aghanian Highlights European Opportunities
Discusses European Generics Pricing, Biosimilars Strategy And Potential For M&A
Dr Reddy’s sees plenty of opportunity in Europe, including for the firm’s burgeoning biosimilars business. However at the same time, current European pricing policies risk exacerbating shortages and are discouraging investment, the firm’s CEO of European operations for global generics, Patrick Aghanian, tells Generics Bulletin in an exclusive interview.
You may also be interested in...
European off-patent industry association Medicines for Europe has welcomed the European Parliament’s “balanced stand” on unitary SPC regulation after “safeguard” provisions allowing pre-grant opposition and explicitly banning patent linkage were adopted.
Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.
Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.